SNES
SenesTechBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
Primary sources support a modestly better commercial profile: 2025 revenue grew to $2.2 million, e-commerce revenue increased, and management described gross-margin improvement alongside a narrower adjusted EBITDA loss [#8-K-2026-03-12].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Amazon direct-management execution is still unproven after an estimated $200,000 2025 revenue hit during the transition [#8-K-2026-03-12].
Momentum
85
Value
41
Sentiment
48
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.55 · Bull $2.10 · Bear $0.75
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-07 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $6.75
Why
Momentum85 · Δ7d -
Value41 · Δ7d -0.1
Sentiment48 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
85
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
48
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade B. Momentum 84.6 / Value 41.1 / Sentiment 48.4
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$7.53M
Beta
0.22
Shares Out
5.3M
P/E (TTM) · Derived
-0.7
P/S (TTM)
5.08
P/FCF (TTM) · Derived
-0.87
Rev YoY
+1.6%
EPS YoY
-69.4%
Gross Margin
+58.5%
Op Margin
-255.6%
Net Debt
-$5.89M
Current Ratio
8.91
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology